Jun Fukihara

Jun Fukihara

Auto-generated profile, based on publicly available information

Jun Fukihara

Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in Respirology
Verified
Journal Article
Open access
PDF file
ASAtsushi Suzuki
Atsushi Suzuki
YKYasuhiro Kondoh
Yasuhiro Kondoh
KBKevin K. Brown
Kevin K. Brown
TJTakeshi Johkoh
Takeshi Johkoh
KKKensuke Kataoka
Kensuke Kataoka
YHYoshinori Hasegawa
Yoshinori Hasegawa
Background and objective: Acute exacerbation (AE) is a severe complication of idiopathic pulmonary fibrosis (AE‐IPF). In 2016, an international working group revised its definition and diagnostic criteria; however, few studies have assessed the frequency and prognosis of AE in patients with other fibrotic interstitial lung diseases (FILD).Methods: We used data from 1019 consecutive interstitial lung disease (ILD) patients initially evaluated between January 2008 and July 2015. All subject diagnoses were made by multidisciplinary discussion in December 2018. ILD was categorized as IPF (n = 462) and other FILD which included non‐specific interstitial pneumonia (n = 22), chronic hypersensitivity pneumonitis (n = 29), connective tissue disease‐associated ILD (n = 205) and unclassifiable ILD (n = 209). Using the 2016 definition of AE‐IPF, we identified all subjects with an AE.Results: During the observational period, 193 patients experienced a first AE (AE‐FILD n = 69, AE‐IPF n = 124). The time to first AE was significantly longer in FILD than IPF (log‐rank test, P < 0.001). After adjusting for potentially influential confounders, FILD remained a significant predictor of longer time to first AE compared with IPF (hazard ratio: 0.453; 95% CI: 0.317–0.647, P = 0.006). In a multivariate Cox proportional analysis, baseline disease severity was closely associated with the incidence of AE‐ILD. Even after adjustment for other clinical variables, AE had a negative impact on overall survival. AE‐FILD and AE‐IPF showed similar poor short‐term outcomes.Conclusion: All forms of ILD are at risk of AE and have a similar outcome to AE‐IPF.

1 November 2019 in Clinical Lung Cancer
Verified
Journal Article
Closed access
JFJun Fukihara
Jun Fukihara
KSKoji Sakamoto
Koji Sakamoto
JKJunji Koyama
Junji Koyama
TITakayasu Ito
Takayasu Ito
SIShingo Iwano
Shingo Iwano
YHYoshinori Hasegawa
Yoshinori Hasegawa

21 March 2008 in Genes to Cells
Verified
Journal Article
Open access
PDF file
MJMayumi Jijiwa
Mayumi Jijiwa
KKKumi Kawai
Kumi Kawai
JFJun Fukihara
Jun Fukihara
ANAkari Nakamura
Akari Nakamura
MHMasaki Hasegawa
Masaki Hasegawa
Masahide TakahashiMasahide Takahashi
Masahide Takahashi
Well‐organized spermatogenesis, including the maintenance of spermatogonial stem cells (SSCs), is indispensable for continuous male fertility. Signaling by glial cell line‐derived neurotrophic factor (GDNF) via the RET/GDNF family receptor α1 (GFRα1) receptor complex is essential for self‐renewal of murine SSCs and may also regulate their differentiation. When phosphorylated, tyrosine 1062 in RET presents a binding site for the phosphotyrosine‐binding domains of several adaptor and effector proteins that are important for activation of a variety of intracellular signaling pathways. In this study, we investigated the role of signaling via RET tyrosine 1062 in spermatogenesis using RET Y1062F knockin mice (Y1062F mice), in which tyrosine 1062 was replaced with phenylalanine. Homozygous Y1062F mice showed marked atrophy of testes due to reduced production of germ cells. RET‐expressing spermatogonia in seminiferous tubules of homozygous Y1062F mice decreased after postnatal day (P) 7 and germ cells were almost undetectable by P21. These phenomena appeared to be due to a lack of SSC self‐renewal and inability to maintain the undifferentiated state. Our findings suggest that RET signaling via tyrosine 1062 is essential for self‐renewal of SSCs and regulation of their differentiation.

20 June 2023 in Respiratory Investigation
Verified
Journal Article
Closed access
JFJun Fukihara
Jun Fukihara
YKYasuhiro Kondoh
Yasuhiro Kondoh

1 September 2020 in Respiratory Investigation
Verified
Journal Article
Closed access
KSKoji Sakamoto
Koji Sakamoto
JFJun Fukihara
Jun Fukihara
MMMasahiro Morise
Masahiro Morise
NHNaozumi Hashimoto
Naozumi Hashimoto

31 October 2016 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
JFJun Fukihara
Jun Fukihara
YKYasuhiro Kondoh
Yasuhiro Kondoh
Nintedanib is a new anti-fibrosis agent that is an intracellular tyrosine kinase inhibitor targeting platelet derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor. Although nintedanib is attracting much attention as a new treatment option for patients with idiopathic pulmonary fibrosis (IPF), the clinical evidence is limited mainly to the results from the dose-deciding phase II TOMORROW trial and phase III INPULSIS trials, which evaluated efficacy and safety of nintedanib for patients with IPF, prespecified subgroup analyses, pooled analyses and meta-analyses derived from those trials. Areas covered: In this document, we mainly reviewed reports on working mechanisms of nintedanib, and efficacy and safety of nintedanib for patients with IPF. The literature search was undertaken using Pub Med. Expert commentary: It is unknown whether the efficacy of nintedanib in patients enrolled in the clinical trials will be the same for the entire spectrum of patients, including patients unfit for the clinical trials due to age, severity, timing of IPF diagnosis or diagnosis of interstitial pneumonias other than IPF. Sufficient consideration should be given when selecting candidates for nintedanib in the real world.